TScan Therapeutics, Inc.

TCRX

Held by 2 specialist biotech funds

Share on X

Fund Holdings

Baker Bros. Advisors BVF Partners

AI Signal

**Signal Note: Baker Bros.

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Activist Filings

SC 13D/ABaker Bros. Advisors6.1%Apr 23, 2024

SC 13D/ABaker Bros. Advisors6.5%Jun 2, 2023

SC 13G/A

Position Details

Baker Bros. AdvisorsNEWFeb 17, 2026

Shares: 2,784,792Value: $2.8M

**Signal Note: Baker Bros. Initiates Large Position in TScan Therapeutics (TCRX)** Baker Bros. building a substantial new position in TCRX is notable given their concentrated, high-conviction style in biotech, though the reported position size (~$2.8B) appears to reflect a data error — TCRX's entire market cap is roughly $50-80M, so the actual dollar value is likely closer to $2.8M at ~$1/share, representing a meaningful ownership stake in this micro-cap. TScan is developing TCR-engineered T-cell therapies targeting solid tumors, with lead program TSC-100 (an allogeneic TCR-T targeting shared neoantigens in solid tumors) in Phase 1; Baker's entry may signal conviction ahead of initial clinical data readouts expected in 2025. Given Baker's track record of early-stage

BVF PartnersNEW

More TCRX Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

AAVXF2 funds FDMT2 funds IRON2 funds IMCR2 funds KYMR2 funds GLUE2 funds RVMD2 funds STOK

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: BVF Partners Initiates TCRX Position **Summary:** BVF Partners established a $5.2M stake in TScan, a clinical-stage immunotherapy company developing T-cell receptor (TCR) therapies for solid tumors and hematologic malignancies. The position suggests conviction in TScan's pipeline, particularly its lead program targeting HPV+ cancers and ongoing Phase 1/2 studies; near-term catalysts include clinical data readouts and potential partnerships that could validate the TCR platform's efficacy in previously difficult-to-treat indications.